Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Head & Neck 1Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Head and Neck Neoplasms 1

Interventions

Cisplatin 57pembrolizumab 54Cetuximab 43Radiotherapy 35Docetaxel 21Radiotherapy, Intensity-Modulated 20Paclitaxel 19Nivolumab 18Fluorouracil 18Carboplatin 17Radiation 14Radiosurgery 9Magnetic Resonance Spectroscopy 8Gemcitabine 8Everolimus 8Biopsy 8Surgical Procedures, Operative 7Oxaliplatin 7Cyclophosphamide 7durvalumab 6avelumab 6Erlotinib Hydrochloride 6Capecitabine 6spartalizumab 5epacadostat 5Surveys and Questionnaires 5Platinum 5Immunoglobulin G 5Gefitinib 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × perifosine × Head & Neck × Clear all
NCT00062387 2013-06-03

Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡